Investors read the deck. They do not believe the commercial story. Partners read the same pages. They see technical risk. Buyers reach for a reference frame and borrow one from the wrong adjacent category. The go-to-market is not a communications problem. It is a translation problem.
Built for life sciences and biotech CEOs. Applies to medtech founders, biopharma BD leaders, and clinical-stage commercial leads, and similar strategic leaders at commercial-stage biotechs.
Commercial narrative. Partner-ready story. Buyer reference-frame architecture. Sequencing that moves a business audience from interest to conviction.
Read the scope →Biotech companies struggle with commercial traction because scientific credibility does not translate automatically into commercial credibility. Investors, partners, and buyers read the same material and reach different conclusions. The work here rebuilds the commercial narrative, aligns the buyer reference frame, and sequences the partner conversation so that a business audience can act on the science. Output is a commercial story investors, partners, and strategic buyers will believe.
The science is not the problem. The translation between the science and the business audience is. These are the three failures that show up in every commercial-stage biotech engagement.
The scientific team is widely published. The asset is validated. The board is stacked. None of that convinces a BD leader at a strategic, a platform lead at a payer, or a partner evaluating an in-license. Those audiences read commercial proof, not scientific proof, and the two vocabularies do not overlap.
When the category is new, the buyer cannot hold it in free space. The buyer imports a reference frame from the closest adjacent incumbent, prices the asset against that frame, and mis-scopes the conversation. The commercial team wastes six months correcting a reference frame that was set in the first meeting.
The deck opens with science. The BD audience needs to see commercial logic, a buyer pathway, a reimbursement or adoption model, and a competitive moat. When the commercial story is buried in the appendix, the partner treats the asset as technical risk rather than a commercial opportunity and the conversation stalls in evaluation.
The engagement starts from the audience, not from the science. The question is not "how do we explain the asset." The question is "what does this audience need to read, in what order, to reach commercial conviction." That reframes every downstream artifact.
Problem one is credibility transfer. The solution is a commercial proof architecture that sits alongside the scientific proof and reads in a vocabulary a business audience uses. Revenue logic, buyer pathway, reimbursement framing, competitive moat, and the commercial evidence that investors and partners need to act.
Problem two is reference frames. The solution is category architecture built for the buyer, not for the team. The engagement identifies the reference frame the buyer is most likely to borrow, then sequences the conversation to migrate the buyer into a correct frame before the asset is evaluated against the wrong one.
Your go-to-market is not a communications problem. It is a translation problem. The science is credible. The translation into commercial language is what is missing.
Problem three is the partnership story. The solution is a partner-ready narrative that opens with commercial logic, leads into scientific proof as substantiation, and closes with a clear, bounded ask. Works for licensing conversations, strategic partnerships, and buy-side BD diligence.
The deliverable is a coherent commercial narrative your CEO can carry into investor conversations, your BD lead can carry into partner conversations, and your commercial team can carry into buyer conversations. One story, three audiences, sequenced for each.
One commercial narrative that reads to investors, partners, and buyers in the language each audience uses. The gap between a credible science story and a credible commercial story closes in one place, not three.
The science is usually credible. The commercial story is not legible to the audience that writes the checks. Investors read the deck and see a research project. Partners read the deck and see technical risk. Buyers read the deck and borrow a reference frame from a wrong adjacent category. The problem is translation, not science, and it is solved by rebuilding the commercial narrative for a business audience.
Commercial-stage biotech, medtech, and biopharma companies with a validated scientific asset and a commercial motion that has outgrown founder-led conversations. Representative clients include therapeutics companies preparing partnership conversations, medtech founders heading into commercial launch, and diagnostics companies in reimbursement and payer strategy. Not pre-asset research groups or academic spinouts without a defined commercial path.
Three recurring patterns. Technical credibility does not transfer to commercial credibility. Buyers borrow reference frames from wrong adjacent incumbents and mis-price the asset. Partnership and licensing conversations stall because the commercial story is not legible to a business audience. The engagement rebuilds the commercial narrative so the business audience can act on it.
The work is commercial translation, not scientific authoring. Your team owns the science. The engagement translates the science into a commercial narrative that investors, partners, and buyers will act on. Prior engagements cover therapeutics, diagnostics, medtech devices, and platform biology. The methodology is portable across therapeutic areas because the commercial translation problem is structurally the same.
Scientific communications firms write for a scientific audience. The work here is the opposite. It translates the science into a commercial narrative for investors, partners, and strategic buyers who do not read journals. The output is a commercial story, a partner-ready narrative, a reference-frame architecture for buyers, and the sequencing that moves a business audience from interest to conviction.
The primary gate is the dedicated life sciences engagement at /for/life-sciences, built for commercial-stage biotech and life sciences CEOs. If the problem is broader than commercial translation, the Marketing Strategy Diagnostic at $5,000 covers positioning, packaging, go-to-market, and demand generation in 10 business days. Both produce a commercial narrative your investors, partners, and buyers can act on.
If you want a senior strategist to review your commercial direction before committing to a full engagement, the founder at stantscherenkow.com works directly with a small number of operators.
Life sciences engagement for commercial-stage biotech, medtech, and biopharma. Commercial narrative, partner-ready story, buyer reference-frame architecture, sequenced for investor, partner, and buyer conversations.
Adjacent industry: Marketing for AI companies. Applied-science GTM dynamics overlap.